Sport and arrhythmias: summary of an international symposium

2007 ◽  
Vol 14 (5) ◽  
pp. 707-714 ◽  
Author(s):  
Franco Giada ◽  
Serge S. Barold ◽  
Alessandro Biffi ◽  
Bruno De Piccoli ◽  
Pietro Delise ◽  
...  
Keyword(s):  
Sudden Death ◽  
Risk Stratification ◽  
International Symposium ◽  
European Society ◽  
Cardiac Arrhythmias ◽  
Exercise Prescription ◽  
International Workshop ◽  
Sport And Exercise ◽  
European Society Of Cardiology

This article is the report of an International Symposium endorsed by the European Society of Cardiology, held within the Venice Arrhythmias 2007: 10th International Workshop on Cardiac Arrhythmias (Venice, October 2007). The topics of the Symposium are the following: how to stratify the risk of sudden death in the athletes; the role of different diagnostic examinations in the risk stratification of sudden death in the athletes; controversies on arrhythmias and sport; and exercise prescription in patients with arrhythmias. Eur J Cardiovasc Prev Rehabil14:707-714 © 2007 The European Society of Cardiology

scholarly journals The Role of Genetics in Cardiomyopaties: A Review

2021 ◽  
Author(s):  
Luis Vernengo ◽  
Haluk Topaloglu
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
European Society ◽  
Cardiac Dysfunction ◽  
American Heart Association ◽  
Heart Association ◽  
The Other ◽  
Systemic Disorder ◽  
European Society Of Cardiology

Cardiomyopathies are defined as disorders of the myocardium which are always associated with cardiac dysfunction and are aggravated by arrhythmias, heart failure and sudden death. There are different ways of classifying them. The American Heart Association has classified them in either primary or secondary cardiomyopathies depending on whether the heart is the only organ involved or whether they are due to a systemic disorder. On the other hand, the European Society of Cardiology has classified them according to the different morphological and functional phenotypes associated with their pathophysiology. In 2013 the MOGE(S) classification started to be published and clinicians have started to adopt it. The purpose of this review is to update it.

Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy

2015 ◽  
Vol 116 (5) ◽  
pp. 757-764 ◽  
Author(s):  
Barry J. Maron ◽  
Susan A. Casey ◽  
Raymond H. Chan ◽  
Ross F. Garberich ◽  
Ethan J. Rowin ◽  
...  
Keyword(s):  
Hypertrophic Cardiomyopathy ◽  
Sudden Death ◽  
European Society ◽  
Risk Model ◽  
Death Risk ◽  
European Society Of Cardiology ◽  
Independent Assessment

scholarly journals Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model

2016 ◽  
Vol 48 (3) ◽  
pp. 780-786 ◽  
Author(s):  
Cecilia Becattini ◽  
Giancarlo Agnelli ◽  
Mareike Lankeit ◽  
Luca Masotti ◽  
Piotr Pruszczyk ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
High Risk ◽  
Risk Stratification ◽  
Negative Predictive Value ◽  
European Society ◽  
Predictive Value ◽  
Acute Pulmonary Embolism ◽  
Risk Stratification Model ◽  
Risk Patients ◽  
European Society Of Cardiology

The European Society of Cardiology (ESC) has proposed an updated risk stratification model for death in patients with acute pulmonary embolism based on clinical scores (Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI)), right ventricle dysfunction (RVD) and elevated serum troponin (2014 ESC model).We assessed the ability of the 2014 ESC model to predict 30-day death after acute pulmonary embolism. Consecutive patients with symptomatic, confirmed pulmonary embolism included in prospective cohorts were merged in a collaborative database. Patients’ risk was classified as high (shock or hypotension), intermediate-high (RVD and elevated troponin), intermediate-low (RVD or increased troponin or none) and low (sPESI 0). Study outcomes were death and pulmonary embolism-related death at 30 days.Among 906 patients (mean±sd age 68±16, 489 females), death and pulmonary embolism-related death occurred in 7.2% and 4.1%, respectively. Death rate was 22% in “high-risk” (95% CI 14.0–29.8), 7.7% in “intermediate-high-risk” (95% CI 4.5–10.9) and 6.0% in “intermediate-low-risk” patients (95% CI 3.4–8.6). One of the 196 “low-risk” patients died (0.5%, 95% CI 0–1.0; negative predictive value 99.5%).By using the 2014 ESC model, RVD or troponin tests would be avoided in about 20% of patients (sPESI 0), preserving a high negative predictive value. Risk stratification in patients at intermediate risk requires further improvement.

scholarly journals Approaches to the Diagnosis and Treatment of Arterial Hypertension in the Light of European Recommendations

Kardiologiia ◽  
2019 ◽  
Vol 59 (9) ◽  
pp. 64-70
Author(s):  
V. N. Larina ◽  
B. Ya. Bart ◽  
E. A. Vartanian ◽  
E. V. Fedorova ◽  
M. P. Mikhailusova ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Drug Treatment ◽  
Arterial Hypertension ◽  
European Society ◽  
Initial Therapy ◽  
Ambulatory Bp Monitoring ◽  
Single Pill ◽  
European Society Of Cardiology

In this review we present analysis the European recommendations on hypertension – what’s new and what has changed in the tactics of managing patients with arterial hypertension (AH). We compared recommendations on hypertension of the European Society of Cardiology (ESC) and the European Society of hypertension (ESH) 2018 with European recommendations of previous years. In the updated version of guidelines, it is still recommended to determine AH as blood pressure (BP) ≥140 and / or ≥90 mm Hg; to subdivide BP levels into optimal, normal, and high normal, to classify severity of AH as 3 degrees, and to distinguish separately its isolated systolic form. Values for out-of-office BP remained unchanged, but recommendations emerged concerning wider use of ambulatory BP monitoring and self-measurement of BP. For initial therapy, it was recommended to use two drugs combinations preferably as single pill combinations. An increase of the role of nurses and pharmacists in teaching, supporting patients and controlling hypertension has been noted. This can improve the achievement of target BP and, as a result, reduce the cardiovascular risk. New European recommendations highlight the modern aspects of classification and diagnosis of AH, main stages of screening, and algorithm of drug treatment of AH.

Sign in / Sign up

Export Citation Format

Share Document